anti-CD45 monoclonal antibody AHN-12
N/A
Report date: 2026/01/26 17:58:57
Base Information
Drug Nameanti-CD45 monoclonal antibody AHN-12
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[5]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Minnesota Masonic Cancer Center
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesMasonic Cancer Center, University Of Minnesota
Active IndicationsN/A
Inactive Indications +[5]
Other Information
ATC CodeN/A
Related LinksN/A